CV Risk Doesn't End in the Cath Lab

Program Themes

Adjusted Risk of All-Cause Death in Post-MI Survivors

Primary Efficacy Endpoint Over Time (PLATO) Composite of CV Death, MI, or Stroke

Primary Endpoint Through Follow-Up in the SOLID-TIMI 52 Trial

68-Year-Old Man: STEMI Treated With BMS

Thrombotic vs Bleeding Risk

Patients Outcomes After Recent Index MI or ADP Blocker Discontinuation

Case 2: 74-Year-Old Woman With NSTEMI

Case 2: Discharge Medications

Intensification of Lipid Therapy?

Additional Risk Factors to Consider

Bleeding Risk Associated With Elevated GDF-15 in Ticagrelor vs Placebo-Treated Patients in PEGASUS

Reasons for and Implications of Elevated GDF-15 Level

Increased Ischemic Risk Identified: What to Consider?

COMPASS: Primary Endpoint* Rivaroxaban Plus Aspirin vs Aspirin Alone

COMPASS: Additional Outcomes

EUCLID Subgroup: Prior Revascularization

PEGASUS: PAD Subgroup

Anti-inflammatory Therapy as Secondary CVD Prevention

Case 3: 58-Year-Old Man With STEMI

Back to Basics: Adherence to Evidence-Based Strategies

LDL-C Reduction: Evidence Points to Lowest Is Best

Effects of Adding Anacetrapib to Intensive Statin Therapy

Cost-Effectiveness Associated With Emerging Strategies

Concluding Comments

Abbreviations

Abbreviations (cont)

Abbreviations (cont)